Takers of GLP-1 are reportedly going on a "holiday pause" to enjoy meal centric family celebrations. Here, an MD breaks down the risks of the trend.

The U.S. Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the ...

FDA has approved the first prescription drug, Zepbound, for treating moderate to severe obstructive sleep apnea (OSA) in adults with obesity.

The US Food and Drug Administration approved a generic once-daily injectable version of the glucagon-like peptide-1 receptor ...

A second study has linked semaglutide, the active ingredient in Ozempic, to a condition that can cause permanent vision ...

The nod, just months after topline results from SURMOUNT-OSA came out, makes it the first drug approved for this indication.

The approval marks the second for a generic in this class of medications indicated to improve glycemic control in patients ...

Connecticut law requires Medicaid to cover certain weight loss drugs, but officials say it hasn't been happening due to cost ...

Body mass index (BMI) and obesity prevalence declined in the United States in 2023, according to a research letter pub ...

Today, the U.S. Food and Drug Administration approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter, a glucagon-like peptide-1 (GLP-1) ...

The U.S. Food and Drug Administration announced Dec. 20 that it has approved Zepbound (tirzepatide) for the treatment of moderate to severe sleep apnea in adults with obesity to be used ...

The history of weight loss medicines reads like a Greek tragedy. However, the biology behind the new GLP-1 agonists suggests ...